News & Updates
Showing Multidisciplinary articles
Showing

Durvalumab plus radiotherapy shows promise in unresectable NSCLC
In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

ESBL-producing, gentamicin-resistant UTI more common during first week of life
A recent study provides further evidence to support the current recommendations for empirical intravenous treatment with gentamicin and ampicillin for febrile infants younger than 2 months with suspected urinary tract infection (UTI).

SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.





